135 related articles for article (PubMed ID: 27878356)
1. Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.
Kunos CA; Chu E; Beumer JH; Sznol M; Ivy SP
Cancer Chemother Pharmacol; 2017 Jan; 79(1):201-207. PubMed ID: 27878356
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.
Schelman WR; Morgan-Meadows S; Marnocha R; Lee F; Eickhoff J; Huang W; Pomplun M; Jiang Z; Alberti D; Kolesar JM; Ivy P; Wilding G; Traynor AM
Cancer Chemother Pharmacol; 2009 May; 63(6):1147-56. PubMed ID: 19082825
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
Gojo I; Tidwell ML; Greer J; Takebe N; Seiter K; Pochron MF; Johnson B; Sznol M; Karp JE
Leuk Res; 2007 Sep; 31(9):1165-73. PubMed ID: 17324462
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
Mortazavi A; Ling Y; Martin LK; Wei L; Phelps MA; Liu Z; Harper EJ; Ivy SP; Wu X; Zhou BS; Liu X; Deam D; Monk JP; Hicks WJ; Yen Y; Otterson GA; Grever MR; Bekaii-Saab T
Invest New Drugs; 2013 Jun; 31(3):685-95. PubMed ID: 22847785
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers.
Kunos CA; Chu E; Makower D; Kaubisch A; Sznol M; Ivy SP
Front Oncol; 2017; 7():62. PubMed ID: 28421163
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.
Kunos CA; Waggoner S; von Gruenigen V; Eldermire E; Pink J; Dowlati A; Kinsella TJ
Clin Cancer Res; 2010 Feb; 16(4):1298-306. PubMed ID: 20145183
[TBL] [Abstract][Full Text] [Related]
8. Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers.
Kunos CA; Andrews SJ; Moore KN; Chon HS; Ivy SP
Front Oncol; 2019; 9():1067. PubMed ID: 31681600
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
Wadler S; Makower D; Clairmont C; Lambert P; Fehn K; Sznol M
J Clin Oncol; 2004 May; 22(9):1553-63. PubMed ID: 15117978
[TBL] [Abstract][Full Text] [Related]
10. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Yee KW; Cortes J; Ferrajoli A; Garcia-Manero G; Verstovsek S; Wierda W; Thomas D; Faderl S; King I; O'brien SM; Jeha S; Andreeff M; Cahill A; Sznol M; Giles FJ
Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz HJ; Lim D; Shibata S; Chung V; Stoller RG; Belani CP; Gandara DR; McNamara M; Gitlitz BJ; Lau DH; Ramalingam SS; Davies A; Espinoza-Delgado I; Newman EM; Yen Y
Cancer Chemother Pharmacol; 2012 Mar; 69(3):835-43. PubMed ID: 22105720
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Giles FJ; Fracasso PM; Kantarjian HM; Cortes JE; Brown RA; Verstovsek S; Alvarado Y; Thomas DA; Faderl S; Garcia-Manero G; Wright LP; Samson T; Cahill A; Lambert P; Plunkett W; Sznol M; DiPersio JF; Gandhi V
Leuk Res; 2003 Dec; 27(12):1077-83. PubMed ID: 12921943
[TBL] [Abstract][Full Text] [Related]
13. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
[TBL] [Abstract][Full Text] [Related]
14. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Karp JE; Giles FJ; Gojo I; Morris L; Greer J; Johnson B; Thein M; Sznol M; Low J
Leuk Res; 2008 Jan; 32(1):71-7. PubMed ID: 17640728
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Ocean AJ; Christos P; Sparano JA; Matulich D; Kaubish A; Siegel A; Sung M; Ward MM; Hamel N; Espinoza-Delgado I; Yen Y; Lane ME
Cancer Chemother Pharmacol; 2011 Aug; 68(2):379-88. PubMed ID: 20981545
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
[TBL] [Abstract][Full Text] [Related]
18. Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.
Kunos CA; Radivoyevitch T; Waggoner S; Debernardo R; Zanotti K; Resnick K; Fusco N; Adams R; Redline R; Faulhaber P; Dowlati A
Gynecol Oncol; 2013 Jul; 130(1):75-80. PubMed ID: 23603372
[TBL] [Abstract][Full Text] [Related]
19. A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.
Martin LK; Grecula J; Jia G; Wei L; Yang X; Otterson GA; Wu X; Harper E; Kefauver C; Zhou BS; Yen Y; Bloomston M; Knopp M; Ivy SP; Grever M; Bekaii-Saab T
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e475-81. PubMed ID: 22818416
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).
Knox JJ; Hotte SJ; Kollmannsberger C; Winquist E; Fisher B; Eisenhauer EA
Invest New Drugs; 2007 Oct; 25(5):471-7. PubMed ID: 17393073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
